-

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company.

The dividend is payable on August 3, 2026, to stockholders of record at the close of business on July 2, 2026.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Summary
Bristol Myers Squibb Announces Dividend
Release Versions
English

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

More News From Bristol Myers Squibb

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

PRINCETON, N.J.--(BUSINESS WIRE)--Mariska Hargitay Partners with BMS for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease...

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.......

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM...
Back to Newsroom